Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

RPRX - Royalty Pharma plc Последние новости | Finranks

Home

/

RPRX

R

Royalty Pharma plc (RPRX)

NMS – Цена в реальном времени. Валюта: USD

58.85

+1.06 (1.83%)

Рынок открыт: Aug 12, 2026, 12:52 PM EDT

58.02

+0.23 (0.40%)

Предыдущая сессия: Aug 11, 2026, 7:43 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline.

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago.

Royalty Pharma reports second quarter 2026 results

Royalty Pharma reports second quarter 2026 results

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Видео

No Data

There is no data to display

Пресс-релизы

Royalty Pharma reports second quarter 2026 results

Royalty Pharma reports second quarter 2026 results

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center.